New pill tested to tame lung damage in cystic fibrosis

NCT ID NCT05865886

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

Summary

This study tested a new medicine called BI 1291583 for adults with cystic fibrosis who also have a lung condition called bronchiectasis. For 12 weeks, participants took either the new tablet or a placebo (dummy pill) to see how safe it was and if it could reduce a harmful enzyme in the lungs linked to damage. The main goal was to check for side effects and see how the drug behaved in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Amsterdam UMC, location VUMC

Amsterdam, 1081 HV, Netherlands
Azienda Ospedaliera Meyer

Florence, 50139, Italy
Azienda Ospedaliera Universitaria Integrata Verona

Verona, 37126, Italy
Charite Universitätsmedizin Berlin KöR

Berlin, 13353, Germany
Hospital Universitari Vall D Hebron

Barcelona, 08035, Spain
Medizinische Hochschule Hannover

Hanover, 30625, Germany
Northwell Health Physician Partners

New York, New York, 10028, United States
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

Essen, 45239, Germany
UZ Leuven

Leuven, 3000, Belgium
Universitair Medisch Centrum Utrecht

Utrecht, 3584 CX, Netherlands
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
Universitätsklinikum Jena

Jena, 07747, Germany

Conditions

Explore the condition pages connected to this study.

BRONCHIECTASIS CYSTIC FIBROSIS